We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022

Continue

Cancel

Pipeline

Therapies in Development

Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest unmet need.
Project Area Phase 1 Phase 2 Phase 3
Lu AF28996 (D1-D2 agonist) Neurology 2
Lu-AF41156 (D2 agonist) Psychiatry 2
Lu AF82422 (anti-alpha-synuclein mAb) Neurology 2
Lu AG06466 (MAGL inhibitor) Neurology, Psychiatry 1
Lu AF87908 (anti-Tau mAb) Neurology 2
Lu AG09222 (anti-PACAP mAb) Neurology 2

More from Lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.

Understanding Brain Diseases

The journey to brain health starts with understanding the diseases in the brain.

Our Commitment

We strive for Progress in Mind - our multifaceted approach to patients.

UK-NOTPR-0467 | April 2022